Stephen Hahn nominated as next FDA Commissioner

2 November 2019

US President Donald Trump on Friday announced his intention to nominate Stephen Hahn to be the next Commissioner of the US Food and Drug Administration.

Dr Hahn has been chief medical executive at The University of Texas MD Anderson Cancer Center (MDACC), Houston, Texas, since May 2018 and Gilbert H Fletcher Memorial Distinguished Chair and Professor of Radiation Oncology at MDACC since January 2015. MDACC is a research-driven patient care organization that has approximately 21,000 employees with an annual revenue of $5 billion and the largest number of clinical trials in the USA.

From 1996-2014, Dr Hahn was at the University of Pennsylvania, where he was Henry K Pancoast Professor and Chair of the Department of Radiation Oncology from 2005-2014. Dr Hahn was a senior investigator at the National Cancer Institute (NCI) from 1989-1996.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK